After successfully being passed by both the house and the senate, PDUFA now waits for the signature of the President to be official once again. PDUFA is the Prescription Drug User Fee Act allows the Food and Drug Administration (FDA) to collect fees from drug manufacturers to supplement Congressional funding to ensure the timely review of new medicines, ultimately enabling innovative, safe, and effective drugs to reach patients more quickly.
For nearly 25 years, the Prescription Drug User Fee Act (PDUFA) has helped increase the number of treatments available to autoimmune disease patients while researchers and scientists search for cures. And with more than 300 medicines in the pipeline for autoimmune diseases, it will be critical that FDA is equipped to keep up with the rapid pace of treatment innovation.
AARDA wants to thank everyone who has contacted their representatives and urged them to vote for the reauthorization and to thank the representatives in the House and Senate who helped pass this legislation.